Signature Global to Raise Rs 875 Cr by August Through Debentures to Refinance Debt, Future Growth
Realty firm Signature Global plans to raise up to Rs 875 crore through issue of non-convertible debentures to refinance debt and expand business.
Signature Global's board approved the raising of funds by issuance of Secured Listed Redeemable Non-Convertible Debentures (NCDs), for an amount not exceeding Rs 875 crore on private placement basis, in one or more tranches.
Signature Global Chairman Pradeep Kumar Aggarwal, said, "We have taken the approval of board to raise funds. We will also seek shareholders approvals."
He said the company will use Rs 450 crore to refinance its existing debt while the remaining amount will be for business growth.
Aggarwal said the company is targeting to raise funds by the end of August, subject to shareholders' approval.
On Wednesday, the board also approved the notice of postal ballot for seeking shareholders' approval for issuance of NCDs, enhancement of borrowing limit, enhancement of limit for creation of security and alteration of Articles of Association of the company.
Gurugram-based Signature Global is one of the leading real estate developers in the country.
In 2024-25 financial year, the company emerged as the fifth largest listed real estate firm in terms of sales bookings. The company sold properties worth Rs 10,290 crore in the last fiscal and is targeting Rs 12,500 crore pre-sales in the current financial year.
Signature Global started its business to develop affordable housing projects, but now it is focusing on mid-income, premium segments because of the high land cost in Gurugram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
Foreign banks offer Torrent ₹20,000 cr credit line for JB Chemicals buyout
The Ahmedabad-based pharmaceutical firm plans to draw down the facility depending on the subscription to its upcoming open offer, the person said, requesting anonymity Mumbai The Torrent group has secured a credit line of up to ₹20,000 crore from a consortium of international lenders, including HSBC, Standard Chartered Bank, and Barclays, to fund its proposed acquisition of JB Chemicals & Pharmaceuticals Ltd, according to a person familiar with the matter. The Ahmedabad-based pharmaceutical firm plans to draw down the facility depending on the subscription to its upcoming open offer, the person said, requesting anonymity. The interest rate on the credit line has been set at a competitive 8 per cent, the person added. Sudhir Menon, chief financial officer at Torrent Pharmaceuticals, told analysts that the
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
KKR's exit from JB Chemicals cements its healthcare track record
KKR & Co's ₹11,900 crore ($1.42 billion) exit from JB Chemicals and Pharmaceuticals marks another successful bet in India's fast-growing healthcare sector, underscoring the US-based private equity giant's strong track record in the space. KKR exited JB Chemicals on Sunday. The sale of its 46.39 per cent stake in JB Chemicals to Torrent Pharmaceuticals comes over four years after KKR acquired control of the company in 2020. The exit follows its blockbuster five-time (5x) return in Max Healthcare in 2022, which remains the largest block deal by a private equity firm in India to date, a person familiar with the matter said. In JB Chemicals, the US-based firm made 36 per cent gross internal rate of return in the exit, including sale of part of its stake via block deal early this year. The JB Chemicals deal adds to KKR's expanding healthcare portfolio in India, which includes stakes in Healthcare Global Enterprises, Baby Memorial Hospital (BMH), Healthium Medtech, and Infinx Healthcare, a US-based healthcare technology firm focused on revenue cycle and patient access solutions. Since the start of 2024, KKR's private equity arm has deployed $2 billion in India. In June, the firm arranged $600 million in financing for the Manipal group through KKR Capital Markets. The deal, anchored by KKR's private credit and insurance platforms, is aimed at supporting Manipal's long-term growth strategy. The Manipal group, which operates Manipal Health Enterprises, one of India's largest multispecialty hospital chains, has been active in the M&A (mergers and acquisitions) market. Manipal had in April 2023 sold a significant stake in its hospital business to Singapore's Temasek Holdings in a transaction valued at nearly $2 billion. KKR's back-to-back healthcare bets come amid rising investor appetite for India's healthcare sector, fuelled by growing demand for quality care, rising incomes, and increased insurance penetration. In 2024, healthcare funding saw an 80 per cent rise in deal volumes, with notable activity in medtech and single-specialty hospitals. The IT/ITeS sector deal value grew 300 per cent, driven by major transactions such as Perficient ($3 billion), Altimetrik ($900 million), and GeBBS ($865 million). Single-specialty hospitals saw particular interest, with deal volumes doubling as investors targeted underpenetrated categories such as eyecare, oncology, and IVF, as per a report by Bain & Company.
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
Piramal Enterprises sees asset under management crossing ₹1 trn in FY26
Piramal Enterprises Chairman Ajay Piramal on Monday said the asset under management (AUM) of the NBFC firm is expected to cross Rs 1 trillion during the current financial year on the back of strong performance. The consolidated AUM grew by 17 per cent to Rs 80,689 crore, exceeding the stated target of 15 per cent growth during FY25, Piramal said while addressing shareholders at the Annual General Meeting (AGM). "With strong performance across our retail and wholesale businesses in FY2025, we are now well positioned to build upon the platform and leverage the investments that have been made. As our three-year transformation journey nears completion, we look ahead with optimism," he said. In FY2026, he said, "we expect to further build on the momentum, growing our total AUM by about 25 per cent to exceed Rs 1 trillion, with growth AUM projected to rise about 30 per cent. Retail lending is expected to contribute 8085 per cent of total AUM." During the 2024-25, Piramal Capital & Housing Finance Ltd was renamed Piramal Finance Ltd. and converted from an NBFC-Housing Finance Company (HFC) to an NBFC-Investment and Credit Company (ICC). Piramal Finance is classified as an upper-layer NBFC and ranks among the top 10 private-sector NBFCs in India. "We have received RBI approval for the merger of Piramal Enterprises and Piramal Finance. The NCLT process is underway and expected to conclude by around September 2025," he said. During FY25, the NBFC had undertaken global borrowings programme, with a total raise of USD 815 million. Of this, USD 550 million was secured through social loans and sustainability-linked bonds. External Commercial Borrowings (ECBs) now constitute 10 per cent of total borrowings, he said. He further said, "Our growth business profits, coupled with monetisation of embedded value, are expected to drive robust earnings in FY2026. We currently estimate consolidated PAT of over Rs 1,300 crore in FY2026, up from Rs 485 crore in FY2025. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
